{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:00:51Z","timestamp":1791925251502,"version":"4.3.4"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Low skeletal muscle mass (LSMM) has been associated with poor prognosis in hepatocellular carcinoma (HCC) patients receiving systemic therapy. However, its impact across different treatment regimens remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective study analyzed 714 patients with intermediate and advanced HCC, divided into immunotherapy (I, n=85), target-immunotherapy combination (I+T, n=545), and targeted therapy (T, n=84) groups based on treatment. Skeletal muscle was assessed via computed tomography (CT) at the third lumbar vertebral level (L3) before and after 3 months of treatment. LSMM was evaluated by the third lumbar skeletal muscle index (L3-SMI) using a predefined threshold. Patients were stratified by baseline values and treatment changes. Kaplan-Meier and Cox models were used to compare overall survival (OS) and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      There was no significant difference in the loss of muscle mass among the three groups of LSMM patients; whereas, non-LSMM(NLSMM) patients in group T lost more muscle mass than those in group I (P=0.040).In the I+T group, patients who achieved an objective response (ORR) had less muscle mass loss than those without (P=0.013), while the changes in muscle mass for patients in the I group and T group were unrelated to treatment response. Baseline or post-treatment LSMM was associated with poorer median OS, especially in the I+T group. Progressive LSMM was linked to shorter median PFS (4.9\n                      <jats:italic>vs<\/jats:italic>\n                      5.7 months) and OS (9.8\n                      <jats:italic>vs<\/jats:italic>\n                      16.5 months), with similar results in the I+T group (mPFS, 4.2\n                      <jats:italic>vs<\/jats:italic>\n                      . 5.8 months; mOS, 9.7\n                      <jats:italic>vs<\/jats:italic>\n                      16.1 months). Patients with LSMM had a higher incidence of treatment-related SAEs, particularly ascites and fatigue.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with combined LSMM in hepatocellular carcinoma, muscle loss did not significantly differ between those treated with I, I+T, and T; however, T treatment contributed to muscle mass loss in NLSMM patients. Greater muscle loss correlated with poorer treatment outcomes and increased SAEs, and baseline, post-treatment, and progressive LSMM were linked to significantly worse prognoses, particularly with combined treatment regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1557839","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:08:41Z","timestamp":1741140521000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The relationship between systemic therapies and low skeletal muscle mass in patients with intermediate and advanced hepatocellular carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingjing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueying","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoxin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00500-6","article-title":"Author correction: hepatocellular carcinoma","volume":"10","author":"Llovet","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02745","article-title":"Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update","volume":"42","author":"Gordan","year":"2024","journal-title":"JCO"},{"key":"B6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000484950","article-title":"Association between loss of skeletal muscle mass and mortality and tumor recurrence in hepatocellular carcinoma: A systematic review and meta-analysis","volume":"7","author":"Chang","year":"2018","journal-title":"Liver Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/jcsm.13161","article-title":"Predictive validity of current sarcopenia definitions (EWGSOP2, SDOC, and AWGS2) for clinical outcomes: A scoping review","volume":"14","author":"Stuck","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2022.978110","article-title":"Association between sarcopenia and prognosis of hepatocellular carcinoma: A systematic review and meta-analysis","volume":"9","author":"Jiang","year":"2022","journal-title":"Front Nutr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2022.04.009","article-title":"Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis","volume":"49","author":"March","year":"2022","journal-title":"Clin Nutr ESPEN"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092426","article-title":"Prevalence and effect of low skeletal muscle mass among hepatocellular carcinoma patients undergoing systemic therapy: A systematic review and meta-analysis","volume":"15","author":"Kuo","year":"2023","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12774","article-title":"Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria","volume":"46","author":"Nishikawa","year":"2016","journal-title":"Hepatol Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1396927","article-title":"Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.031","article-title":"Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma","volume":"63","author":"Fujiwara","year":"2015","journal-title":"J Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1159\/000503829","article-title":"Skeletal muscle loss during tyrosine kinase inhibitor treatment for advanced hepatocellular carcinoma patients","volume":"9","author":"Uchikawa","year":"2020","journal-title":"Liver Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14143551","article-title":"Clinical usefulness of monitoring muscle volume during atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma","volume":"14","author":"Matsumoto","year":"2022","journal-title":"Cancers"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/nu9101054","article-title":"Sarcopenia impairs prognosis of patients with hepatocellular carcinoma: the role of liver functional reserve and tumor-related factors in loss of skeletal muscle volume","volume":"9","author":"Imai","year":"2017","journal-title":"Nutrients"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2012.04347.x","article-title":"Low testosterone levels as an independent predictor of mortality in men with chronic liver disease","volume":"77","author":"Grossmann","year":"2012","journal-title":"Clin Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.583478","article-title":"Exercise-induced autophagy suppresses sarcopenia through Akt\/mTOR and Akt\/FoxO3a signal pathways and AMPK-mediated mitochondrial quality control","volume":"11","author":"Zeng","year":"2020","journal-title":"Front Physiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/ncb2757","article-title":"ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase","volume":"15","author":"Russell","year":"2013","journal-title":"Nat Cell Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.01-12-0584","article-title":"Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake","volume":"13","author":"Edinger","year":"2002","journal-title":"MBoC"},{"key":"B22","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.clcc.2019.04.003","article-title":"Regorafenib is associated with increased skeletal muscle loss compared to TAS-102 in metastatic colorectal cancer","volume":"18","author":"Huemer","year":"2019","journal-title":"Clin Colorectal Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2139-4","article-title":"Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma","volume":"71","author":"Chan","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198812","article-title":"Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma","volume":"13","author":"Takada","year":"2018","journal-title":"PloS One"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15336","article-title":"Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting","volume":"36","author":"Hiraoka","year":"2021","journal-title":"J Gastro Hepatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1159\/000504604","article-title":"Skeletal muscle mass influences tolerability and prognosis in hepatocellular carcinoma patients treated with lenvatinib","volume":"9","author":"Uojima","year":"2020","journal-title":"Liver Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1380477","article-title":"The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors","volume":"15","author":"Sun","year":"2024","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123243","article-title":"Relationship between accurate diagnosis of sarcopenia and prognosis in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab combination therapy","volume":"15","author":"Oura","year":"2023","journal-title":"Cancers"},{"key":"B29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/COC.0000000000000787","article-title":"Impact of sarcopenia, BMI, and inflammatory biomarkers on survival in advanced hepatocellular carcinoma treated with anti-PD-1 antibody","volume":"44","author":"Akce","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.12.005","article-title":"Skeletal muscle cells actively shape (auto)immune responses","volume":"17","author":"Afzali","year":"2018","journal-title":"Autoimmun Rev"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.10.034","article-title":"Skeletal muscle as potential central link between sarcopenia and immune senescence","volume":"49","author":"Nelke","year":"2019","journal-title":"eBioMedicine"},{"key":"B32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1053\/j.seminoncol.2018.08.006","article-title":"Aging, immune senescence, and immunotherapy: A comprehensive review","volume":"45","author":"Elias","year":"2018","journal-title":"Semin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"7157","DOI":"10.1038\/s41598-018-25628-w","article-title":"Sarcopenia as a predictor of post-transplant tumor recurrence after living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria","volume":"8","author":"Kim","year":"2018","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40520-016-0705-4","article-title":"Physical activity and exercise as countermeasures to physical frailty and sarcopenia","volume":"29","author":"Marzetti","year":"2017","journal-title":"Aging Clin Exp Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1370-x","article-title":"Supplementation with branched-chain amino acids ameliorates hypoalbuminemia, prevents sarcopenia, and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis","volume":"53","author":"Kitajima","year":"2018","journal-title":"J Gastroenterol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/nu13124428","article-title":"Levocarnitine supplementation suppresses lenvatinib-related sarcopenia in hepatocellular carcinoma patients: results of a propensity score analysis","volume":"13","author":"Okubo","year":"2021","journal-title":"Nutrients"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1557839\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T02:08:44Z","timestamp":1741140524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1557839\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":36,"alternative-id":["10.3389\/fimmu.2025.1557839"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1557839","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"article-number":"1557839"}}